This case report presents a patient with advanced diffuse panbronchiolitis accompanied by chronic respiratory failure, marked cachexia, and refractory spontaneous pneumothorax.
The current data suggest that the patholosiology of DPB is similar to that of cystic fibrosis and bronchiectasis. End-stage DPB is occasionally complicated by pneumothorax , which makes treatment more difficult.
In cases of prolonged air leakage in which a fistula on the surface of lung dose not close and no bronchial fistula is present, we usually start treatment with long-term tube thoracostomy and instillation of a pleurodesis agent. Thoracoscopy will be considered only when theses treatments are unsuccessful. However surgery itself poses a significant risk for patients whose physical condition and lung function have deteriorated.
Coagulation factor XIII stabilizes fibrin at the final stage of homeostasis, stabilizes fibrinogen, and stops bleeding. It is also an important factor for restoring organization and wound healing 1 . Therefore, a fall in the activity of coagulation factor XIII is an obstacle to the wound healing and is a cause of prolonged air leakage in refractory pneumothorax.
We report on a patient with refractory peumothorax, a poor general condition, and a decreased pulmonary function who we successfully F i g . 1 P l a i n c h e s t r o e n t g e n o g r a ms Th e l e f t s i d e ( A) s h o ws p e u mo t h o r a x wi t h a d r a i n a g e t u b e , a n d t h e r i g h t s i d e ( B ) s h o ws t h e r e -e x p a n d e d l u n g a f t e r i n f u s i o n o f f a c t o r X I I I . treated with infusion of coagulation factor XIII concentrate.
Case Report
A 49-year-old Japanese woman with a 6-year history of advanced DPB was treated with erythromycin, 600 mg daily, and had received oxygen therapy over the previous 2 years. She was admitted to our hospital because of hypercapnia ( !O2 Fig. 1-B) . The patient then started rehabilitation because of generalized muscle atrophy during hospitalization. She was discharged on the 79 th day. The activity of coagulation factor
t o r X I I I wa s l o w a t 5 6 %, c o a g u l a t i o n f a c t o r X I I I c o n c e n t r a t e wa s a g a i n g i v e n i n t r a v e n o u s l y f o r 5 d a y s , f r o m t h e 5 1 s t t o t h e 5 5 t h d a y . Ai r l e a k a g e r e s o l v e d o n t h e 5 5 t h d a y . Th e d r a i n a g e t u b e wa s c l a mp e d o n t h e 6 3 r d d a y a n d wa s r e mo v e d 2 d a y s l a t e r . Th e p a t i e n t wa s d i s c h a r g e d o n t h e 7 9 t h d a y .
XIII was 83% at the time of discharge.
Discussion
Secondary spontaneous pneumothorax in DPB is However, a large amount of coagulation factor XIII is needed to enhance wound healing 11, 12 . Other reports have also recognized the beneficial effects of factor XIII replacement therapy in patients with acute therapy-resistant ulcerative colitis 13 and Crohn!s disease fistulas 14 .
Therefore, we administered coagulation factor XIII intravenously to a patient with refractory pneumothorax and advanced DPB.
We were able to stop the prolonged air leakage and treat refractory pnemothorax with a coagulation factor XIII concentrate. Therefore, we recommend coagulation intravenous administration of factor XIII concentrate (3"6 vials! day, 5 days) with the The present patient required rapid treatment, because P. aeruginosa was isolated from the sputum.
Infection with P. aeruginosa is usually a problem in advanced DPB and increases the risk of pyothorax and sepsis. Gradual weight loss caused by DPB and respiratory failure was another reason to avoid pleurodesis, fibrin infusion into the thorax, or surgery, which are likely to cause further restrictive ventilatory impairment.
After a thorough review of this case, we concluded that infusion of coagulation factor XIII concentrate might be an effective treatment for patients with refractory pneumothorax in addition to aspiration, tube thoracostomy, instillation of a pleurodesis agent and thoracosopy, although its costeffectiveness must be improved.
